Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).

Takayuki Nakayama,Makiko Yamashita,Toshihiro Suzuki,Manami Shimomura,Tetsuya Nakatsura,Kazunori Aoki,Noboru Yamamoto,Naoya Yamazaki,Taiki Isei,Hisashi Uhara,Yoshio Kiyohara,Hiroshi Uchi,Hiroshi Saruta,Takashi Inozume,Maki Tanaka,Shigehisa Kitano

Immunological impact of canerpaturev (C-REV, formerly HF10), an oncolytic viral immunotherapy, with or without ipilimumab (Ipi) for advanced solid tumor patients (pts).

2019

Takayuki Nakayama
Makiko Yamashita
Toshihiro Suzuki
Manami Shimomura
Tetsuya Nakatsura
Kazunori Aoki
Noboru Yamamoto
Naoya Yamazaki
Taiki Isei
Hisashi Uhara
Yoshio Kiyohara
Hiroshi Uchi
Hiroshi Saruta
Takashi Inozume
Maki Tanaka
Shigehisa Kitano

2610Background: C-REV, an oncolytic, spontaneous mutant of Herpes Simplex Virus type 1 (HSV-1), is a cancer immunotherapy agent that combine direct tumor cell killing with immune modulation. A phas...

Keywords:

Oncolytic virus
Ipilimumab
Immunotherapy
Advanced Solid Tumor
Oncology
Pathology
Medicine
Internal medicine
immune modulation
tumor cells
Herpes simplex virus
Cancer immunotherapy
Cancer research

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations